| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d5fe74855697fef20a2e98a9b005db19 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4045
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4858
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4875 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4045
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-52 |
| filingDate |
1995-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2001-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bd0023a48a7c67487402b129914bc292
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_be4d9f9a32a94896fe757373b1d51642
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6aa22f0a2ec0ae14a7cd7d5a9b41ea98
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_73643faaad5f510d4f2605c79a17b333
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3716c8a09a8e43f851c19822609ed0c2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ba3cbd43030b2301e28de0870bc439ce |
| publicationDate |
2001-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-6214377-B1 |
| titleOfInvention |
Melatonin for the production of a peroral pulsatile form of medication |
| abstract |
The use of melatonin for the production of peroral pulsatile forms of medications assures the safeguard of an effective level of the medical substance of melatonin in the blood, and which realize a relatively short invasion phase with a controlled delivery in comparison to conventional forms of medication containing melatonin, and which simultaneously exclude the known side effects. A control of the delivery of the melatonin is effected which is associated with the precise adaptation to the illness episodes or the pain attacks of certain illnesses, which can be treated prophylactically and therapeutically with the active agent melatonin. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9549900-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11389428-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9532952-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010120887-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6703412-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10226447-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10143654-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005129751-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005082143-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008148015-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9186351-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9241926-B2 |
| priorityDate |
1994-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |